vialroom

#retatrutide 2025-06-22

Sunday24 messages5 participantstimes are UTC
Highlights from this day
  • hiccup_hollis — reconstituted the 10 vial to 2.5mg/ml specifically so i could take 10 without measuring crumbs 13:58
  • hiccup_hollis — sat at 15 for 4 months rather than climbing and it kept working, so i never went up 13:59
  • ferrous_ash — right so back after 19 months, has anything actually been published since 15:12
  • dose_down_dara — anyone gone above 2 and what changed 15:53
  • ferrous_ash — how do people square the research use only framing with logging their own use 16:33
OW

unrelated but whats the half life like, is it weekly the same way

HH

does the glucagon arm explain the heart rate or is that unrelated

👍1
HH

reconstituted the 10 vial to 2.5mg/ml specifically so i could take 10 without measuring crumbs

👀11

sat at 15 for 4 months rather than climbing and it kept working, so i never went up

🤝1😂1

lost 6kg over 18 months at doses well under what the trials used

RR

i log resting heart rate every morning because of this and its the one number i actually watch

follow up i went up too fast, got a fortnight of nothing but nausea, and dropped back two steps

FA

right so back after 19 months, has anything actually been published since

🔥16💀12🙏1
FA

people insist on small steps because the side effects arrive faster than on the other two

HH

came off at 25 weeks because my resting rate stayed elevated and i didnt like it, i think

DD

anyone gone above 2 and what changed

baseline  58
wk 2      61
wk 4      64
wk 6      67
wk 8      66
wk 10     65   (held dose from wk 7)

triple agonist meaning GLP-1, GIP and glucagon, have i got that right

HH

blood pressure stayed flat for me while heart rate moved, which i didnt expect

OW

slightly off topic but appetite suppression at 5 was stronger than my tirzepatide experience at a comparable point

FA

coming back to this is the GI worse than tirzepatide or about the same

FA

how do people square the research use only framing with logging their own use

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

phase 2 only

OW

sorry to jump in held at 2 for 19 months and it never plateaued for me, which i cant explain